Nontargeted metabolomics uncovering metabolite signatures in glioblastoma: a preliminary study on candidate biomarker discovery for IDH subtyping and survival prediction
{{output}}
Background: Currently, there are no established tumor-derived metabolic biomarkers in clinical practice that can simultaneously differentiate among nontumorous brain tissues, isocitrate dehydrogenase (IDH) wild-type glioblastomas... ...
